March 21, 1983
Our Reference: 82-196
Michael B. Rodell, Ph.D.
Travenol Laboratories, Inc.
Hyland Therapeutics Division
444 West Glenoaks Boulevard
Glendale, CA. 91202
Dear Mr. Rodell:
The amendment to your product license for Antihemophilic Factor (Human) to allow for an optional heat treatment of final containers has been approved. This information will be made a part of your files.
Please submit stability data for the six month and twelve month intervals and then the subsequent information as it becomes available.
Sincerely yours,
John C. Petricciani, M.D.
Director
National Center for Drugs and Biologics
